Mergers & Acquisitions ·
Cumberland Pharmaceuticals reports Q3 net income of $77.8M following $100M Apotex deal
CPIXCumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc. reported third-quarter 2026 net income of $77.8 million, driven by an $81.1 million gain on the divestiture of its commercial business to Apotex Health for $100 million in July. The transaction closed on July 1, 2026, and proceeds have strengthened the balance sheet with $80.6 million in cash as of September 30. The company is now focused exclusively on its clinical pipeline, announcing plans to submit a New Drug Application for ifetroban to treat cardiomyopathy associated with Duchenne muscular dystrophy. Top-line results from a Phase 2 trial for systemic sclerosis were also disclosed. Cumberland Pharmaceuticals Inc. operates in the biopharmaceutical industry, developing therapies for rare diseases.